March 2026
Ketamine
What March 2026's 25 new studies found, synthesized from the papers below. All Ketamine research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ketamine, esketamine, arketamine, then ranked by relevance.
Research on ketamine in March 2026 focused on esketamine for treatment-resistant depression (TRD), showing that mystical experiences during treatment are common and linked to better outcomes, and that esketamine does not cause cognitive decline and may improve attention. Real-world studies found high response and remission rates (70% and 68%) but noted that greater treatment refractoriness predicts lower odds of response. A key caveat is that most evidence comes from observational studies and reviews, with limited long-term safety data and few studies in special populations like adolescents.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study 2026 | observational | 45 | Supports | Mystical experiences occurred in 58% of patients and were associated with greater improvement in depression scores, while dissociative effects were not. |
| Clinical applications of esketamine: Current status and future perspectives. 2026 | review | Supports | Esketamine is increasingly used for surgical anesthesia, analgesia, and pain management, with a comprehensive summary of its clinical applications and adverse effects. | |
| Acute ketamine withdrawal disrupts memory and monoaminergic neurotransmission in adolescent female rats. 2026 | preclinical | 8 | Opposes | Acute ketamine withdrawal after recreational-like exposure impaired episodic, social, and working memory in adolescent female rats. |
| Ketamine as a Rapid-Acting Antidepressant: A Scoping Review of Mechanisms and Efficacy in Treatment-Resistant Depression. 2026 | review | Supports | Ketamine shows rapid-acting antidepressant effects in TRD through glutamatergic modulation, but long-term safety and dependence risk require evaluation. | |
| Underlying Mechanisms of the Treatment Efficacy of (R, S)‐Ketamine for Post‐Traumatic Stress Disorder and Depression: A Review 2026 | review | Supports | Ketamine and its stereoisomers show efficacy for PTSD and TRD, with (R)-ketamine having reduced abuse potential, and mechanisms involve multiple brain regions. | |
| Cognitive Effects of Esketamine in Treatment-Resistant Depression: A Systematic Review. 2026 | systematic review | Supports | Esketamine does not cause cognitive deterioration and may improve attention and processing speed, with memory improvements in longer-term studies. | |
| Distinct Molecular Responses to Ketamine and Imipramine in Cortical and Striatal Regions Following Acute Swim Stress 2026 | preclinical | Mixed | Ketamine preserved stress-evoked neuronal activation in cortex and striatum, unlike imipramine, indicating distinct molecular mechanisms despite similar behavioral outcomes. | |
| Ketamine Use in Self-Described Therapeutic Contexts: A Thematic Analysis of Reddit Posts 2026 | qualitative | 500 | Mixed | Users reported mood improvements (65%) but also psychological adverse effects (56%), with frequent high-dose use and polydrug exposure highlighting the need for monitoring. |
| Esketamine nasal spray for treatment-resistant depression: A retrospective multicenter real-world cohort study on effectiveness and suicidal outcomes. 2026 | observational | 50 | Supports | Significant improvements in depression and functioning were observed, with 70% response and 68% remission rates; higher refractoriness predicted lower odds of response. |
| [Esketamine alleviates depression-like behaviors in mice with chronic restraint stress by activating glutamatergic neurons in the medial prefrontal cortex]. 2026 | preclinical | 150 | Supports | Esketamine alleviated depression-like behaviors by activating glutamatergic neurons in the medial prefrontal cortex. |
| Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil. 2026 | observational | 28 | Unclear | Athletes showed openness to psychedelic therapies but had significant knowledge gaps and misconceptions; ketamine was not specifically studied. |
| Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response. 2026 | observational | Unclear | Abstract only; no details on findings. | |
| Editorial: Retuning the Adolescent Brain: Esketamine and Rapid Structural Change in the rACC. 2026 | editorial | Supports | Esketamine may produce faster symptom relief in adolescent MDD, but its neural mechanisms in the developing brain are incompletely understood. | |
| Cannabidiol Mitigates Ketamine-Induced Hyperlocomotion Via Allosteric Potentiation of Ventral Tegmental Glycine Receptor α1 Signaling. 2026 | preclinical | Supports | Cannabidiol mitigated ketamine-induced hyperlocomotion by reversing ketamine's suppression of glycine receptor function in the ventral tegmental area. | |
| Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review 2026 | review | Supports | Esketamine may reduce drug-seeking behavior and cravings in TRD patients with comorbid substance use disorders, especially when combined with behavioral interventions. | |
| Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression with Comorbid Autism Spectrum Disorder: Three Case Reports. 2026 | case series | 3 | Supports | Intranasal esketamine showed clinical response in three patients with TRD and comorbid autism, with improvements in depressive symptoms and social cognition over six months. |
| The renaissance of research on psychedelics in child and adolescent psychopharmacology 2026 | review | Supports | Psychedelic research, including esketamine, is expanding to pediatric populations, but translation requires caution due to developmental vulnerabilities. | |
| Esketamine Suppresses Astrocyte-Driven Neuroinflammation in Traumatic Brain Injury via the METTL5/c-Myc/PD-L1 2026 | preclinical | Supports | Esketamine improved neurological outcomes and reduced neuroinflammation after TBI by suppressing astrocyte activation via the METTL5/c-Myc/PD-L1 pathway. | |
| Ketamine for comorbid treatment-resistant depression and substance use disorders: balancing risks and opportunities 2026 | review | Mixed | Individuals with comorbid SUDs may be overrepresented among responders to ketamine for TRD, but risks of misuse must be carefully balanced. | |
| Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS. 2026 | observational | Unclear | Abstract only; no details on findings. | |
| Neuroprotective Effects of Esketamine in Central Nervous System Disorders: Mechanisms and Cellular Targets 2026 | review | Supports | Esketamine has neuroprotective effects in CNS disorders through anti-inflammatory, antiapoptotic, and antioxidant mechanisms, targeting neurons, microglia, and astrocytes. | |
| Neuronal Population Effects of Ketamine on Human Brain Organoids 2026 | preclinical | Opposes | Acute ketamine abolished population bursting in organoids by disconnecting 'backbone' units, and chronic exposure induced tolerance with reduced network activity. | |
| Effect of Ketamine on Reward Processing in Depressive Disorders: A Systematic Review of Neuroimaging Studies 2026 | systematic review | 623 | Supports | Ketamine modulates fronto-striatal and limbic reward circuitry, with effects on ventral striatal connectivity and reward processing, suggesting a mechanism for alleviating anhedonia. |
| Esketamine Implementation Challenges in Psychiatry: A Qualitative Analysis of Mental Healthcare Providers’ Social Media Commentary 2026 | qualitative | 186 | Opposes | Implementation challenges for esketamine include billing/reimbursement issues, staffing, and logistical barriers, with negative sentiment toward reimbursement and manufacturer. |
| Intranasal esketamine for treatment-resistant depression: real-world effectiveness in electroconvulsive therapy non-responders 2026 | observational | 60 | Supports | Intranasal esketamine reduced MADRS scores from 33.9 to 15.7 at 6 months, with no significant difference in response between ECT non-responders and others. |
Mystical experiences occurred in 58% of patients and were associated with greater improvement in depression scores, while dissociative effects were not.
observational Sample size: 45
Esketamine is increasingly used for surgical anesthesia, analgesia, and pain management, with a comprehensive summary of its clinical applications and adverse effects.
review
Acute ketamine withdrawal after recreational-like exposure impaired episodic, social, and working memory in adolescent female rats.
preclinical Sample size: 8
Ketamine shows rapid-acting antidepressant effects in TRD through glutamatergic modulation, but long-term safety and dependence risk require evaluation.
review
Ketamine and its stereoisomers show efficacy for PTSD and TRD, with (R)-ketamine having reduced abuse potential, and mechanisms involve multiple brain regions.
review
Esketamine does not cause cognitive deterioration and may improve attention and processing speed, with memory improvements in longer-term studies.
systematic review
Ketamine preserved stress-evoked neuronal activation in cortex and striatum, unlike imipramine, indicating distinct molecular mechanisms despite similar behavioral outcomes.
preclinical
Users reported mood improvements (65%) but also psychological adverse effects (56%), with frequent high-dose use and polydrug exposure highlighting the need for monitoring.
qualitative Sample size: 500
Significant improvements in depression and functioning were observed, with 70% response and 68% remission rates; higher refractoriness predicted lower odds of response.
observational Sample size: 50
Esketamine alleviated depression-like behaviors by activating glutamatergic neurons in the medial prefrontal cortex.
preclinical Sample size: 150
Athletes showed openness to psychedelic therapies but had significant knowledge gaps and misconceptions; ketamine was not specifically studied.
observational Sample size: 28
Abstract only; no details on findings.
observational
Esketamine may produce faster symptom relief in adolescent MDD, but its neural mechanisms in the developing brain are incompletely understood.
editorial
Cannabidiol mitigated ketamine-induced hyperlocomotion by reversing ketamine's suppression of glycine receptor function in the ventral tegmental area.
preclinical
Esketamine may reduce drug-seeking behavior and cravings in TRD patients with comorbid substance use disorders, especially when combined with behavioral interventions.
review
Intranasal esketamine showed clinical response in three patients with TRD and comorbid autism, with improvements in depressive symptoms and social cognition over six months.
case series Sample size: 3
Psychedelic research, including esketamine, is expanding to pediatric populations, but translation requires caution due to developmental vulnerabilities.
review
Esketamine improved neurological outcomes and reduced neuroinflammation after TBI by suppressing astrocyte activation via the METTL5/c-Myc/PD-L1 pathway.
preclinical
Individuals with comorbid SUDs may be overrepresented among responders to ketamine for TRD, but risks of misuse must be carefully balanced.
review
Abstract only; no details on findings.
observational
Esketamine has neuroprotective effects in CNS disorders through anti-inflammatory, antiapoptotic, and antioxidant mechanisms, targeting neurons, microglia, and astrocytes.
review
Acute ketamine abolished population bursting in organoids by disconnecting 'backbone' units, and chronic exposure induced tolerance with reduced network activity.
preclinical
Ketamine modulates fronto-striatal and limbic reward circuitry, with effects on ventral striatal connectivity and reward processing, suggesting a mechanism for alleviating anhedonia.
systematic review Sample size: 623
Implementation challenges for esketamine include billing/reimbursement issues, staffing, and logistical barriers, with negative sentiment toward reimbursement and manufacturer.
qualitative Sample size: 186
Intranasal esketamine reduced MADRS scores from 33.9 to 15.7 at 6 months, with no significant difference in response between ECT non-responders and others.
observational Sample size: 60
Points of agreement
- Esketamine is effective for treatment-resistant depression in real-world settings, with response rates around 70% and remission rates around 68%.
- Esketamine does not cause cognitive decline and may improve attention and processing speed.
- Mystical or psychoactive effects during esketamine treatment are common and may be linked to better antidepressant outcomes.
- Ketamine's antidepressant effects involve modulation of glutamatergic signaling, BDNF, and synaptic plasticity in prefrontal-limbic circuits.
Conflicts
- One preclinical study found that acute ketamine withdrawal impaired memory in adolescent rats, while human studies suggest esketamine is cognitively safe or beneficial.
- Qualitative data from Reddit users reported frequent high-dose use and adverse psychological effects, whereas clinical trials emphasize safety and tolerability.
- Implementation challenges (billing, logistics) contrast with the positive efficacy data, suggesting a gap between research and practice.
Gaps
- Long-term safety and dependence risk of ketamine/esketamine remain understudied.
- Few studies focus on adolescents and special populations (e.g., autism, PTSD) with adequate sample sizes.
- Mechanisms linking mystical experiences to therapeutic outcomes are not fully understood.
- Comparative effectiveness against other rapid-acting treatments (e.g., rTMS) is lacking.
- Real-world data on esketamine in comorbid substance use disorders is limited to reviews and case series.